EXOMIND

Overview

EXOMIND is BTL Industries' entry in the tms devices category, built on ExoTMS (patented external TMS with proprietary coil design). The platform treats dorsolateral prefrontal cortex, with under 30 minutes per session and a recommended course of 6 sessions (significantly fewer than competitors). FDA cleared in 2024, it lists in the $100,000-$200,000 range for new units and Limited secondary market (too new) on the secondary market.

FDA-cleared for depression in just 6 sessions (vs 20-36 for competitors). Also cleared in Canada/EU for anxiety, OCD, and binge eating. The mechanism is what separates EXOMIND from competitors in the same category. Where it fits in your practice depends on patient demographics, treatment volume, and whether you need a flagship platform or a value-tier alternative.

EXOMIND is manufactured by BTL Industries (Prague, Czech Republic, founded 1993). The device benefits from BTL Industries' long manufacturer history and presence across 90+ countries. Service support, training availability, and parts access vary by region. Practices considering this device should validate dealer presence and technical support coverage in their area before signing a contract.

Pros & Cons

Clinical Evidence

Emerging. FDA clearance data is available. Full peer-reviewed evidence base still developing. The published evidence base for EXOMIND reflects how long the platform has been in market and how much the manufacturer has invested in clinical research. Devices with FDA clearance dates before 2018 typically have stronger peer-reviewed datasets than newer entrants. For physicians evaluating this device, the questions worth asking are whether the studies used blinded evaluators, what the sample sizes were, and whether the research was independent or manufacturer-funded.

Compare EXOMIND's evidence base against the category benchmark. In EXOMIND's category, the strongest evidence typically comes from devices that have been on the market for at least five years and have multiple randomized controlled trials with independent funding. Marketing claims from any manufacturer should be cross-checked against PubMed-indexed publications rather than conference posters or white papers. Conference presentations are not equivalent to peer review.

For practices that require strong clinical evidence (academic dermatology, plastic surgery groups with research interests, multi-physician practices that need to defend purchase decisions internally), the evidence profile should be a top-three decision factor. For high-volume cash-pay practices where patient demand drives device selection, brand recognition often matters more than the underlying evidence base. Both approaches are defensible, but they lead to different device selections.

ROI Analysis

Practice ROI for EXOMIND depends on three variables: capital cost, per-session revenue, and treatment volume. At a new unit price of $100,000-$200,000, financed over five years at typical equipment rates, the monthly payment runs roughly 2-2.5% of total cost. Per-session revenue at TBD (emerging pricing) means the device needs to fill enough treatment slots monthly to cover the payment, consumables (TBD), maintenance (TBD), and operator labor.

For a practice doing 2-3 treatments per day at the midpoint of the per-session range, EXOMIND typically reaches break-even at 12-18 months for the lower end of the new pricing range, or 18-30 months at the high end. Used and refurbished units in the Limited secondary market (too new) range can cut payback periods in half. The biggest practice mistake is over-projecting treatment volume. Physicians who run their numbers on 4-6 daily treatments rarely hit those targets in year one.

The realistic question is not whether EXOMIND can pay back. Most devices in this price range do, eventually. The question is whether your practice can fill the schedule. Practices with existing patient flow in Psychiatry, Neurology have the easiest path. Practices building demand from scratch should plan for 6-12 months of marketing investment before the device pays for itself.

Best For

Psychiatrists or multi-specialty practices already in the BTL ecosystem. Early adopters willing to bet on the 6-session protocol advantage. The fit is strongest for practices that match the device's positioning on price, clinical evidence requirements, and patient throughput expectations. Practices with mismatched economics often regret these purchases within 18 months.

Beyond practice type, EXOMIND fits best when the patient base aligns with the device's strengths. For tms devices platforms, this usually means matching device capability to patient demographics, skin type range, and willingness to pay per-session pricing. Practices in markets where patients price-shop heavily need to factor that into device selection. Practices in concierge or luxury markets can charge premium pricing that justifies premium platforms.

Buying Guide

New EXOMIND units sell for $100,000-$200,000 from BTL Industries or authorized dealers. Refurbished and used units sell for Limited secondary market (too new) on the secondary market. The decision between new and used comes down to warranty coverage, software version, included applicators, and consumable allowances. New units typically include a 12-24 month warranty, current software, all applicators, and a starter consumable package. Used units usually carry no warranty, may have outdated software, and require separate consumable purchases.

What to negotiate: applicator quantity (always ask for additional applicators thrown in), consumable starter packs, training and certification fees, extended warranty coverage, marketing materials, and clinical training for additional providers. BTL Industries sales reps typically have 10-15% list price flexibility and significantly more on bundled deals. End-of-quarter and end-of-year are the strongest negotiation windows. Trade-in programs for older devices can reduce net cost by another 10-20%.

What to watch for: software lock-out fees on used units (some manufacturers disable software on resold devices), per-pulse or per-treatment licensing fees that show up after purchase, consumable price increases over the device life, and service contract terms. Always require a written quote that breaks out hardware, applicators, training, first-year service, and consumables separately. Bundled quotes hide the line items where margins live.

Alternatives and Comparisons

The main alternatives to EXOMIND in this category are listed below. Click into any comparison for a full side-by-side breakdown.